EHF and lung carcinoma: For example, the loss of EHF has been found to promote epithelial-mesenchymal transition and cell migration in conditions such as prostate cancer (18, 19), lung cancer (20, 21), pancreatic cancer, and esophageal squamous cell carcinoma.